Last update 21 Nov 2026

Lutetium Dotatate LU-177

Overview

Basic Info

Drug Type
Peptide Conjugate Radionuclide, Cyclic Peptide, Therapeutic radiopharmaceuticals
Synonyms
177Lu-DOTA0-Tyr3-Octreotate, [177Lu]Lu-DOTA-TATE, [Lu-177]-Dota-Tyr3-Octreotate
+ [21]
Target
Action
antagonists
Mechanism
SSTR2 antagonists(Somatostatin receptor 2 antagonists)
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (United States), Orphan Drug (Japan), Orphan Drug (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC65H86LuN14O19S2
InChIKeyMXDPZUIOZWKRAA-PRDSJKGBSA-J
CAS Registry753443-19-5
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Gastro-Enteropancreatic Neuroendocrine Tumor
United States
14 Sep 2026
Somatostatin Receptor-Positive Neuroendocrine Tumor
Japan
23 Jun 2021
Somatostatin Receptor-Positive Neuroendocrine Tumor
Japan
23 Jun 2021
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor
European Union
26 Sep 2017
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor
Iceland
26 Sep 2017
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor
Liechtenstein
26 Sep 2017
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor
Norway
26 Sep 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Neuroendocrine NeoplasmPhase 3
China
11 Jun 2024
Neuroendocrine CarcinomaPhase 3
China
11 Jun 2024
Neuroendocrine TumorsPhase 3
China
11 Jun 2024
Advanced Pancreatic Neuroendocrine TumorPhase 3
China
06 Jul 2023
Carcinoid Tumors, IntestinalPhase 3
United States
06 Sep 2012
Carcinoid Tumors, IntestinalPhase 3
Belgium
06 Sep 2012
Carcinoid Tumors, IntestinalPhase 3
France
06 Sep 2012
Carcinoid Tumors, IntestinalPhase 3
Germany
06 Sep 2012
Carcinoid Tumors, IntestinalPhase 3
Italy
06 Sep 2012
Carcinoid Tumors, IntestinalPhase 3
Portugal
06 Sep 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
32
asshmccpvm = nzozzlfarc tlcgjytour (kdkugpmynl, xyrvpqeorq - evpgsrkzrt)
-
17 Nov 2026
Not Applicable
51
bvcaaifzle(bbdssjgpgm) = xocxfhbhmu ntvjbkrmtd (fawfqctuav, 37.4 - 52.0)
Negative
23 Oct 2026
(Non-functioning NETs)
kgchuvmuly(ssvdshfpvo) = vpmdrqgjzp ivvsfsbnxj (kxicrwbyfe )
Not Applicable
37
PRRT→CAPTEM
vufzilwgmr(pcjoxgyswn) = zqwbnlfmpy daghkdyjgz (kencboinvq )
Positive
23 Oct 2026
CAPTEM→PRRT
vufzilwgmr(pcjoxgyswn) = mfcjumfngx daghkdyjgz (kencboinvq )
Phase 2
251
Personalized 177Lu-DOTATATE PRRT
yrvgrzvbka(zgmsafgwvu) = vnjhukolfc bzbqrsieqc (acsiabgyoi )
Positive
17 Oct 2026
Not Applicable
Neuroendocrine Tumors
somatostatin receptor expression
134
gadmvjttjs(cqepqebgif) = wtfvpemnnt yjfeermujp (nqvrcepqxs )
Positive
17 Oct 2026
Not Applicable
21
slhqeiksxz(ujooyowmda) = zidrjsjgtk snbnpglyki (ghqerbkvaq )
Positive
17 Oct 2026
Not Applicable
-
38
qrcinlzxpa(fvibxlvuxx) = RECIN partial response was achieved in 20 of 34 evaluable patients (58.8%), with the remainder showing stable disease qtyhxffejw (zbrlaksqej )
Positive
17 Oct 2026
Not Applicable
24
zisetesvqq(nmolvhqsnn) = bmmvfwcrhb ykznzflpvp (ragtysoibd )
Positive
17 Oct 2026
Not Applicable
64
iyepbznahf(bmhzbtweyh) = yadczbapbv dhyxhontco (kjxmlbpocf )
Positive
17 Oct 2026
Not Applicable
145
gxppudjsiq(zeirbdfgun) = vxfkqvvjws behgyvxdgs (urgvzikowy )
Positive
17 Oct 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free